Novo Nordisk (NVO) just reported 2 year results from its evoke and evoke+ phase 3 trials in early-stage symptomatic Alzheimer’s disease - and the market did not like what it saw.
The trials, which enrolled 3,808 adults, tested oral semaglutide versus placebo on top of standard of care. Despite improvements in Alzheimer’s-related biomarkers, semaglutide did not show superiority in slowing disease progression on the key CDR-SB cognitive scale.
Based on these results, Novo is discontinuing the planned 1 year extension of both studies. The company notes that semaglutide’s safety profile remained consistent with prior trials and highlights more than 37 million patient-years of exposure across diabetes and obesity populations. Benzinga
Earlier this morning, NVO shares were trading about 10.7% lower around 42.34 dollars premarket, as investors quickly removed the Alzheimer’s upside from the story. Benzinga
Topline data will be presented at the CTAD conference on December 3, 2025, with full results coming at the AD/PD 2026 meeting.
Be the first to comment